Trial Profile
A Multicentre Feasibility Randomized Study of Anti-PD-L1 Durvalumab (MEDI4736) With or Without Anti-CTLA-4 Tremelimumab in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma, Treated With a First-line Neo-adjuvant Strategy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Acronyms INeOV
- Sponsors ARCAGY/GINECO Group
- 28 Jul 2023 Planned End Date changed from 30 Apr 2023 to 28 Feb 2024.
- 28 Jul 2023 Planned primary completion date changed from 30 Apr 2023 to 28 Feb 2024.
- 06 Jun 2023 Results assessing good pathological response to NACT +D+/-T is associated with high levels of both T cells and macrophages in iTME at baseline, and increased intratumoral T cell infiltration post-treatment, presented at the 59th Annual Meeting of the American Society of Clinical Oncology